Walter, R. B., Michaelis, L. C., Othus, M., Uy, G. L., Radich, J. P., Little, R. F., … Erba, H. P. (2018). Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol, 93(2), E49–E52. https://doi.org/10.1002/ajh.24980

Walter, Roland B., Laura C. Michaelis, Megan Othus, Geoffrey L. Uy, Jerald P. Radich, Richard F. Little, Sandi Hita, et al. “Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.” Am J Hematol 93, no. 2 (February 2018): E49–52. https://doi.org/10.1002/ajh.24980.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, et al. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018 Feb;93(2):E49–52.

Walter, Roland B., et al. “Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.” Am J Hematol, vol. 93, no. 2, Feb. 2018, pp. E49–52. Pubmed, doi:10.1002/ajh.24980.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018 Feb;93(2):E49–E52.